Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 4/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 4/20 | 0.38 |
| ▸ | RELA | Q04206 | 4/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28269645 | 0.69 | NFKB1 (0.42) | NFKB1NFKB2RELACA1CA2 | |
| SCHEMBL27991298 | 0.69 | NFKB1 (0.42) | NFKB1NFKB2RELACA1CA2 | |
| SCHEMBL1559073 | 0.66 | NFKB1 (0.38) | NFKB1NFKB2RELACA1CA2 | |
| SCHEMBL19512667 | 0.65 | NFKB1 (0.40) | NFKB1NFKB2RELACA1CA2 | |
| SCHEMBL18808294 | 0.64 | GAA (0.43) | NFKB1NFKB2RELAGAA | |
| SCHEMBL17991583 | 0.64 | NFKB1 (0.49) | NFKB1NFKB2RELAGAA | |
| SCHEMBL14072074 | 0.64 | ATR (0.39) | NFKB1NFKB2RELAGAAMAPKAPK2 | |
| SCHEMBL29032266 | 0.64 | NFKB1 (0.39) | NFKB1NFKB2RELACA1CA2 | |
| SCHEMBL15500654 | 0.63 | LCK (0.36) | NFKB1NFKB2RELACA1CA2 | |
| SCHEMBL31363590 | 0.63 | DRD2 (0.33) | NFKB1NFKB2RELACA1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210009519-A1 | HISTONE DEACETYLASE INHIBITORS | BIOMARIN PHARMACEUTICAL INC. | 2021-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009519-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC2, HDAC3 | NFKB1 2428/4885NFKB2 2029/4885RELA 965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.